Tag: Enjaymo
Press release: European Commission approves Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adults with cold agglutinin disease – 11/17/2022 at 6:50 p.m.
The European Commission approves Enjaymo ® (sutimlimab) for treatment of hemolytic anemia in adults suffering from cold agglutinin disease Enjaymo is the first and only approved treatment option for the…
Sanofi: European favorable opinion for Enjaymo
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Sanofi: European favorable opinion for Enjaymo – 09/16/2022 at 16:21
(CercleFinance.com) – The Scientific Committee of the European Medicines Agency (EMA) yesterday issued a favorable opinion concerning the granting of a marketing authorization for Enjaymo, Sanofi’s treatment for patients with…
Sanofi: European positive opinion for Enjaymo
(CercleFinance.com) – The Scientific Committee of the European Medicines Agency (EMA) yesterday issued a favorable opinion concerning the granting of a marketing authorization for Enjaymo, Sanofi’s treatment for patients with…
Sanofi: approval of Enjaymo in the United States
(CercleFinance.com) – Sanofi announces that the United States FDA has approved Enjaymo (sutimlimab-jome) to reduce the need for red blood cell transfusions to treat hemolysis in adults with cold agglutinin…
Sanofi: approval of Enjaymo in the United States – 02/07/2022 at 08:00
(CercleFinance.com) – Sanofi announces that the United States FDA has approved Enjaymo (sutimlimab-jome) to reduce the need for red blood cell transfusions to treat hemolysis in adults with cold agglutinin…
Sanofi: FDA approves Enjaymo to treat cold agglutinin disease
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced Friday evening that the Food and drug administration (FDA), the American health authority, had approved its drug Enjaymo, to reduce the use of…